|Mr. Mark J. Levin||Exec. Chairman||73k||N/A||1950|
|Mr. Bryan E. Stuart||Pres, CEO & Director||598.4k||N/A||1976|
|Mr. Curtis G. Oltmans J.D.||Sr. VP, Gen. Counsel & Corp. Sec.||83.98k||N/A||1963|
|Dr. Bradley E. Bernstein||Founder||N/A||N/A||N/A|
|Dr. Michael R. Green||Founder||N/A||N/A||N/A|
|Dr. Rudolf Jaenisch Ph.D., M.D.||Founder||N/A||N/A||N/A|
|Prof. Jeannie T. Lee M.D., Ph.D.||Founder||N/A||N/A||N/A|
|Dr. Danny Reinberg||Founder||N/A||N/A||N/A|
|Mr. Peter G. Thomson||VP of Fin. & Accounting||N/A||N/A||N/A|
|Dr. Christopher Moxham Ph.D.||Chief Scientific Officer||N/A||N/A||1968|
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Fulcrum Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 9.